OBR Daily Commentary

forumImage

2021 GU Cancers Symposium: Apalutamide Combo Boosts PFS in ACIS Trial of mCRPC

(OBR) Feb 11, 2021 - Combining apalutamide (APA) with abiraterone acetate plus prednisone (AAP) reduced the risk of radiographic progression or death by 31% in patients with advanced prostate cancer who had never received chemotherapy, according to findings presented at the American Society of Clinical Oncology’s 2021 Genitourinary Cancers Symposium. This combination yielded stronger outcomes than AAP alone, especially in certain patient subgroups, said Dana E. Rathkopf, MD, who presented the final results of ACIS, a randomized, double-blind, phase 3 study (Abstract 9) of patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).

Read Article arrow

Tomasz Beer (Posted: February 11, 2021)

quotes

This study demonstrated an improvement in progression-free survival but not overall survival with increased toxicity and cost. Because the comparison was between apalutamide + abiraterone and abiraterone alone, we don't know whether apalutamide alone would compare favorably to abiraterone.

quotes

Reply

Add Comment 1 Comment(s)

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics Professo...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Steven Spielberg Family Chair in Hematology Oncology P...

member photo
Stephen M. Schleicher, M.D., MBA

Community Oncology, Medical Oncologist, OneOncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...